Osteoporosis International

, Volume 31, Issue 1, pp 77–84 | Cite as

Fracture liaison service and mortality in elderly hip fracture patients: a prospective cohort study

  • D. González-QuevedoEmail author
  • D. Bautista-Enrique
  • V. Pérez-del-Río
  • M. Bravo-Bardají
  • D. García-de-Quevedo
  • I. Tamimi
Original Article



Osteoporosis is a metabolic disorder that results in increased bone fragility and risk of fractures. Hip fracture is the most important fragility fracture. Fracture Liaison Service (FLS) is a secondary prevention model which identifies patients at risk for fragility fractures. The introduction of an intensive FLS model could decrease 1-year-mortality of hip fracture patients.


Hip fractures are a clinical manifestation of osteoporosis, and these patients are at risk of premature death and suffering subsequent fractures. FLS is an approach for secondary facture prevention by identifying patients with fragility fractures and initiating the appropriate treatment. Our objective is to analyze the effect of the FLS model over the first-year mortality rates following a hip fracture.


We conducted a prospective cohort study on patients over 60 years of age who suffered a hip fracture during two consecutive years, before and after the implementation of the FLS in our center (i.e., between January 2016 and December 2017). Patients’ information was withdrawn from our local computerized database. Patients were followed for 1 year after the hip fracture. Mortality and re-fracture rates were compared between the two groups using a multivariate Cox proportional hazard model.


A total of 724 individuals were included in this study (i.e., 357 before FLS implementation and 367 after FLS implementation). Anti-osteoporotic drugs were more frequently prescribed after FLS implementation [275 (74.9%) vs 44 (12.3%); p < 0.01]. A total of 74 (20.2%) patients after FLS implementation and 92 (25.8%) individuals before FLS implementation (p = 0.07) died during the follow-up period. A second fracture occurred in 17 (4.6%) patients after FLS implementation and 13 (3.6%) individuals before FLS implementation (p = 0.50). Patients who were treated with anti-osteoporotic drugs after the implementation of the FLS protocol had a lower 1-year mortality compared with patients managed before the implementation of the FLS protocol (treated or not treated with anti-osteoporotic drugs) [adjusted hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.47–0.94; p < 0.05].


We did not observe significant 1-year-mortality differences following a hip fracture between patients treated before the implementation of an FLS protocol and patients treated after its implementation. The application of the FLS did not affect the risk of suffering a second osteoporotic fracture. However, patients treated with anti-osteoporotic drugs in an FLS context had a lower mortality rate compared with patients managed before the implementation of the FLS.

Level of clinical evidence



Fracture liaison service Hip fractures Osteoporosis Mortality Survival Re-fracture 


Funding information

This research did not receive any specific grant from funding agencies in the public, commercial or not-profit sectors.

Compliance with ethical standards

Conflicts of interest

D. González-Quevedo, D. Bautista-Enrique, V. Pérez-del-Rio, M. Bravo-Bardají and D. García-de-Quevedo have received in the last 5 years honoraria for lecture fees or financial support for attending symposia from Lilly and Amgen. I. Tamimi reports no conflict of interest.


  1. 1.
    Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Bliuc D, Nguyen ND, Milch VE (2010) Mortality risk associated with low-trauma fracture in men and women. Jama 301:513–521. CrossRefGoogle Scholar
  3. 3.
    Flais J, Coiffier G, Le Noach J et al (2017) Low prevalence of osteoporosis treatment in patients with recurrent major osteoporotic fracture. Arch Osteoporos 12:24. CrossRefPubMedGoogle Scholar
  4. 4.
    Miller AN, Lake AF, Emory CL (2015) Establishing a fracture liaison service: an orthopaedic approach. J Bone Joint Surg Am 97:675–681. CrossRefPubMedGoogle Scholar
  5. 5.
    Walters S, Khan T, Ong T, Sahota O (2017) Fracture liaison services: improving outcomes for patients with osteoporosis. Clin Interv Aging 12:117–127. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Briot K (2017) Fracture liaison services. Curr Opin Rheumatol 29:416–421. CrossRefPubMedGoogle Scholar
  7. 7.
    Ganda K, Puech M, Chen JS, Speerin R, Bleasel J, Center JR, Eisman JA, March L, Seibel MJ (2013) Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int 24:393–406. CrossRefPubMedGoogle Scholar
  8. 8.
    Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57. CrossRefPubMedGoogle Scholar
  9. 9.
    Huntjens KMB, van Geel T a CM, van den Bergh JPW et al (2014) Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality. J Bone Joint surgery American 96:e29. CrossRefGoogle Scholar
  10. 10.
    Hawley S, Kassim Javaid M, Prieto-Alhambra D et al (2016) Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study. Age Ageing 45:236–242. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Dreinhöfer KE, Mitchell PJ, Bégué T, Cooper C, Costa ML, Falaschi P, Hertz K, Marsh D, Maggi S, Nana A, Palm H, Speerin R, Magaziner J, on behalf of: the Fragility Fracture Network (FFN), European Geriatric Medicine Society (EuGMS), European Federation of National Associations of Orthopaedics and Traumatology (EFORT), International Collaboration of Orthopaedic Nursing (ICON), International Geriatric Fracture Society (IGFS), International Osteoporosis Foundation (IOF) (2018) A global call to action to improve the care of people with fragility fractures. Injury 49:1393–1397. CrossRefPubMedGoogle Scholar
  12. 12.
    Cree MW, Juby AG, Carriere KC (2003) Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int 14:722–727. CrossRefPubMedGoogle Scholar
  13. 13.
    Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Nurmi-Lüthje I, Sund R, Juntunen M, Lüthje P (2011) Post-hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs is associated with lower mortality: a nationwide study in Finland. J Bone Miner Res 26:1845–1853. CrossRefPubMedGoogle Scholar
  15. 15.
    van Geel TACM, Bliuc D, Geusens PPM, Center JR, Dinant GJ, Tran T, van den Bergh JPW, McLellan AR, Eisman JA (2018) Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: a prospective cohort study. PLoS One 13:e0198006. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Autier P (2007) Vitamin D supplementation and Total mortality<subtitle>a meta-analysis of randomized controlled trials</subtitle>. Arch Intern Med 167:1730–1737. CrossRefPubMedGoogle Scholar
  17. 17.
    Avenell A, Mak JC, O’Connell D (2014) Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev.
  18. 18.
    on the behalf of the Study group, Degli Esposti L, Girardi A et al (2018) Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk. Endocrine. 64:367–377. CrossRefGoogle Scholar
  19. 19.
    Makridis KG, Karachalios T, Kontogeorgakos VA, Badras LS, Malizos KN (2015) The effect of osteoporotic treatment on the functional outcome, re-fracture rate, quality of life and mortality in patients with hip fractures: a prospective functional and clinical outcome study on 520 patients. Injury 46:378–383. CrossRefPubMedGoogle Scholar
  20. 20.
    Bynum JPW, Bell J-E, Cantu RV, Wang Q, McDonough CM, Carmichael D, Tosteson TD, Tosteson ANA (2016) Second fractures among older adults in the year following hip, shoulder, or wrist fracture. Osteoporos Int 27:2207–2215. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Doherty DA, Sanders KM, Kotowicz MA, Prince RL (2001) Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int 12:16–23. CrossRefPubMedGoogle Scholar
  22. 22.
    Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Melton LJ III, Atkinson EJ, Cooper C et al (1999) Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214–221. CrossRefPubMedGoogle Scholar
  24. 24.
    Bottai V (2016) Underdiagnosis of osteoporotic vertebral fractures in patients with fragility fractures: retrospective analysis of over 300 patients. ccmbm.
  25. 25.
    McLellan AR, Gallacher SJ, Fraser M, McQuillian C (2003) The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 14:1028–1034. CrossRefPubMedGoogle Scholar
  26. 26.
    Bliuc D, Nguyen ND, Nguyen TV, Eisman JA, Center JR (2013) Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men: mortality risk after osteoporotic fracture/refracture in the elderly. J Bone Miner Res 28:2317–2324. CrossRefGoogle Scholar
  27. 27.
    Ip TP, Leung J, Kung AWC (2010) Management of osteoporosis in patients hospitalized for hip fractures. Osteoporos Int 21:605–614. CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Klop C, Gibson-Smith D, Elders PJM, Welsing PMJ, Leufkens HGM, Harvey NC, Bijlsma JWJ, van Staa TP, de Vries F (2015) Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010. Osteoporos Int 26:1919–1928. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Saito T, Sterbenz JM, Malay S, Zhong L, MacEachern MP, Chung KC (2017) Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. Osteoporos Int 28:3289–3300. CrossRefPubMedGoogle Scholar
  30. 30.
    Mo J, Huang K, Wang X et al (2018) The sensitivity of orthopaedic surgeons to the secondary prevention of fragility fractures, vol 100, p 13Google Scholar
  31. 31.
    Vrignaud A, Pelletier S, Dernis E, Moui Y, Haettich B (2018) Improvement in the primary and secondary prevention of osteoporosis by a fracture liaison service: feedback from a single French center care pathway. Arch Osteoporos 13:110. CrossRefPubMedGoogle Scholar
  32. 32.
    Sobolev B, Sheehan KJ, Kuramoto L, Guy P (2015) Risk of second hip fracture persists for years after initial trauma. Bone 75:72–76. CrossRefPubMedGoogle Scholar
  33. 33.
    Omsland TK, Emaus N, Tell GS, Ahmed LA, Center JR, Nguyen ND, Gjesdal CG, Forsmo S, Schei B, Søgaard AJ, Meyer HE (2013) Ten-year risk of second hip fracture. A NOREPOS study. Bone 52:493–497. CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2019

Authors and Affiliations

  1. 1.Department of Orthopedic Surgery and TraumatologyRegional University Hospital of MálagaMálagaSpain

Personalised recommendations